Genetic contributors to serum uric acid levels in Mexicans and their effect on premature coronary artery disease.


Journal

International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291

Informations de publication

Date de publication:
15 Mar 2019
Historique:
received: 16 02 2018
revised: 23 08 2018
accepted: 25 09 2018
pubmed: 12 10 2018
medline: 18 12 2019
entrez: 12 10 2018
Statut: ppublish

Résumé

Serum uric acid (SUA) is a heritable trait associated with cardiovascular risk factors and coronary artery disease (CAD). Genome wide association studies (GWAS) have identified several genes associated with SUA, mainly in European populations. However, to date there are few GWAS in Latino populations, and the role of SUA-associated single nucleotide polymorphisms (SNPs) in cardiovascular disease has not been studied in the Mexican population. We performed genome-wide SUA association study in 2153 Mexican children and adults, evaluated whether genetic effects were modified by sex and obesity, and used a Mendelian randomization approach in an independent cohort to study the role of SUA modifying genetic variants in premature CAD. Only two loci were associated with SUA levels: SLC2A9 (β = -0.47 mg/dl, P = 1.57 × 10 SUA elevation was independently associated with premature CAD, metabolic syndrome and decreased eGFR in the Mexican population. However, a Mendelian randomization approach using the lead SUA-associated SNPs (SLC2A9 and ABCG2) did not support a causal role of elevated SUA levels for premature CAD.

Sections du résumé

BACKGROUND BACKGROUND
Serum uric acid (SUA) is a heritable trait associated with cardiovascular risk factors and coronary artery disease (CAD). Genome wide association studies (GWAS) have identified several genes associated with SUA, mainly in European populations. However, to date there are few GWAS in Latino populations, and the role of SUA-associated single nucleotide polymorphisms (SNPs) in cardiovascular disease has not been studied in the Mexican population.
METHODS METHODS
We performed genome-wide SUA association study in 2153 Mexican children and adults, evaluated whether genetic effects were modified by sex and obesity, and used a Mendelian randomization approach in an independent cohort to study the role of SUA modifying genetic variants in premature CAD.
RESULTS RESULTS
Only two loci were associated with SUA levels: SLC2A9 (β = -0.47 mg/dl, P = 1.57 × 10
CONCLUSIONS CONCLUSIONS
SUA elevation was independently associated with premature CAD, metabolic syndrome and decreased eGFR in the Mexican population. However, a Mendelian randomization approach using the lead SUA-associated SNPs (SLC2A9 and ABCG2) did not support a causal role of elevated SUA levels for premature CAD.

Identifiants

pubmed: 30305239
pii: S0167-5273(18)31073-8
doi: 10.1016/j.ijcard.2018.09.107
pii:
doi:

Substances chimiques

Biomarkers 0
Uric Acid 268B43MJ25

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

168-173

Informations de copyright

Copyright © 2018 Elsevier B.V. All rights reserved.

Auteurs

Luis R Macias-Kauffer (LR)

Programa de Maestría y Doctorado en Ciencias Médicas, Odontológicas y de la Salud, Universidad Nacional Autónoma de México (UNAM), Mexico City, Mexico; Unidad de Genómica de Poblaciones Aplicada a la Salud, Facultad de Química, UNAM/Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City, Mexico.

Hugo Villamil-Ramírez (H)

Unidad de Genómica de Poblaciones Aplicada a la Salud, Facultad de Química, UNAM/Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City, Mexico.

Paola León-Mimila (P)

Unidad de Genómica de Poblaciones Aplicada a la Salud, Facultad de Química, UNAM/Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City, Mexico.

Leonor Jacobo-Albavera (L)

Laboratorio de Enfermedades Cardiovasculares, INMEGEN, Mexico City, Mexico.

Carlos Posadas-Romero (C)

Departamento de Endocrinología, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico.

Rosalinda Posadas-Sánchez (R)

Departamento de Endocrinología, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico.

Blanca E López-Contreras (BE)

Unidad de Genómica de Poblaciones Aplicada a la Salud, Facultad de Química, UNAM/Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City, Mexico.

Sofía Morán-Ramos (S)

Unidad de Genómica de Poblaciones Aplicada a la Salud, Facultad de Química, UNAM/Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City, Mexico.

Sandra Romero-Hidalgo (S)

Departamento de Genómica Computacional, INMEGEN, Mexico City, Mexico.

Víctor Acuña-Alonzo (V)

Escuela Nacional de Antropología e Historia, Mexico City, Mexico. UCL Genetics Institute, University College London, London WC1E 6BT, UK.

Blanca E Del-Río-Navarro (BE)

Hospital Infantil de México Federico Gómez, Mexico City 06720, Mexico.

Maria-Cátira Bortolini (MC)

Departamento de Genética, Universidade Federal do Rio Grande do Sul, Porto Alegre 91501-970, Brazil.

Carla Gallo (C)

Laboratorios de Investigación y Desarrollo, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima 31, Peru.

Gabriel Bedoya (G)

GENMOL (Genetica Molecular), Universidad de Antioquia, Medellin 5001000, Colombia.

Francisco Rothhammer (F)

Instituto de Alta Investigación, Universidad de Tarapacá e ICBM Facultad de Medicina Universidad de Chile, 1000009, Chile.

Rolando González-Jose (R)

Instituto Patagónico de Ciencias Sociales y Humanas (CENPAT-CONICET), U9120ACD Puerto Madryn, Argentina.

Andrés Ruiz-Linares (A)

Ministry of Education Key Laboratory of Contemporary Anthropology and Collaborative Innovation Center of Genetics and Development, School of Life Sciences and Human Phenome Institute, Fudan University, Shanghai, China; Aix-Marseille Univ, CNRS, EFS, ADES, Marseille, France.

Christopher R Stephens (CR)

C3-Centro de Ciencias de la Complejidad e Instituto de Ciencias Nucleares, UNAM, Ciudad de México, Mexico.

Rafael Velazquez-Cruz (R)

Laboratorio de Genómica del Metabolismo Óseo, Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City, Mexico.

Cecilia Fernández Del Valle-Laisequilla (C)

Investigación Clínica y Farmacovigilancia, Productos Medix, S.A. de C.V., Mexico City, Mexico.

Juan G Reyes-García (JG)

Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico City, Mexico.

Lina M Barranco Garduño (LM)

Unidad de Investigación en Farmacología, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico.

Miriam Del C Carrasco-Portugal (MDC)

Unidad de Investigación en Farmacología, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico.

Francisco J Flores-Murrieta (FJ)

Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico City, Mexico; Unidad de Investigación en Farmacología, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico.

Gilberto Vargas-Alarcón (G)

Departamento de Biología Molecular, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico.

Carlos A Aguilar-Salinas (CA)

Unidad de Investigación en Enfermedades Metabólicas and Departamento de Endocrinología y Metabolismo, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico; Tecnológico de Monterrey, Escuela de Medicina y Ciencias de la Salud. Monterrey, N.L., Mexico.

Teresa Villarreal-Molina (T)

Laboratorio de Enfermedades Cardiovasculares, INMEGEN, Mexico City, Mexico. Electronic address: mvillareal@inmegen.gob.mx.

Samuel Canizales-Quinteros (S)

Unidad de Genómica de Poblaciones Aplicada a la Salud, Facultad de Química, UNAM/Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City, Mexico. Electronic address: cani@unam.mx.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH